SCHEMBL17167546

SCHEMBL17167546

CCCCCOC(O)C(OS(=O)(=O)O)C(O)C(CC(=O)O)OC1OC(COS(=O)(=O)O)C(OC2OC(C(=O)O)C(OC3OC(COS(=O)(=O)O)C(O)C(O)C3C)C(O)C2OS(=O)(=O)O)C(O)C1C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ F10 P00742 4/20 0.45
▸ VEGFA P15692 5/20 0.39
▸ CXCL12 P48061 3/20 0.39
▸ BMP2 P12643 2/20 0.39
▸ SHH Q15465 2/20 0.39
▸ BDNF P23560 3/20 0.37
▸ PTN P21246 2/20 0.37
▸ MDK P21741 2/20 0.37
▸ CCL2 P13500 2/20 0.37
▸ IFNG P01579 1/20 0.37
▸ PF4 P02776 1/20 0.37
▸ SELP P16109 1/20 0.37
▸ BMP6 P22004 1/20 0.37
▸ CCL11 P51671 1/20 0.37
▸ WNT3A P56704 1/20 0.37
▸ SELPLG Q14242 1/20 0.37
▸ SERPINC1 P01008 1/20 0.36
▸ CXCL10 P02778 1/20 0.36
▸ CXCL8 P10145 1/20 0.36
▸ CCL5 P13501 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17167545 0.89 F10 (0.43) F10VEGFACXCL12BMP2SHH
SCHEMBL17167853 0.89 F10 (0.43) F10VEGFACXCL12BMP2SHH
SCHEMBL17167763 0.87 SELP (0.33) VEGFABDNFPTNMDKSELP
SCHEMBL17167857 0.82 F10 (0.53) F10VEGFACXCL12BMP2SHH
SCHEMBL18914846 0.82 — —
SCHEMBL18915133 0.80 MDK (0.39) F10VEGFACXCL12BMP2SHH
SCHEMBL17167540 0.80 TLR4 (0.35) VEGFASELPFGF2HPSEFGF1
SCHEMBL17167539 0.79 BDNF (0.51) F10VEGFACXCL12BMP2SHH
SCHEMBL18914918 0.78 MDK (0.40) F10VEGFACXCL12BMP2SHH
SCHEMBL18914844 0.76 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170152279-A9 Saccharide Dendritic Cluster Compounds as Inhibitors of Bace-1 UNIVERSITY OF LIVERPOOL (GB) 2017-06-01 — — US disclosed
US-20150291644-A1 Saccharide Dendritic Cluster Compounds as Inhibitors of Bace-1 VICTORIA LINK LTD (NZ) 2015-10-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150291644-A1 Saccharide Dendritic Cluster Compounds as Inhibitors of Bace-1 BACE1, BACE2, APP F10 3347/4885VEGFA 4518/4885CXCL12 305/4885
US-20170152279-A9 Saccharide Dendritic Cluster Compounds as Inhibitors of Bace-1 BACE1, BACE2, APP F10 3347/4885VEGFA 4518/4885CXCL12 305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback